Acute therapies and disease-modifying therapies for multiple sclerosis

Khurram Bashir, Dean Marko Wingerchuk

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating CNS disease for which several immunomodulatory and immunosuppressive strategies have been shown to reduce evidence of disease activity and preserve neurological function. High-dose parenteral corticosteroid therapy speeds recovery from acute attacks of MS, including optic neuritis. Severe, corticosteroid-refractory attacks may respond to plasma exchange. Following a first-ever demyelinating event (clinically isolated syndrome), treatment with glatiramer acetate, intramuscular interferon ß-1a, or subcutaneous interferon ß-1b reduces the risk of the development of clinically definite MS over the subsequent 2–3 years.

Original languageEnglish (US)
Title of host publicationNeurology: An Evidence-Based Approach
PublisherSpringer New York
Pages273-291
Number of pages19
ISBN (Print)9780387885551, 9780387885544
DOIs
StatePublished - Jan 1 2012

Keywords

  • Clinically isolated syndrome
  • Diagnosis
  • Disease modifying therapy
  • Epidemiology
  • Evidence-based medicine
  • Multiple sclerosis
  • Optic neuritis
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Acute therapies and disease-modifying therapies for multiple sclerosis'. Together they form a unique fingerprint.

Cite this